Michael Jardula
Internal Medicine · Palm Springs, CANPI 1346222510
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,346 of the $10,239 with a category attached, or 62.0%. 36 manufacturers reported payments, led by Eli Lilly at 24.7% of the total. Reporting peaked in 2024 at $3,499 and has fallen 88.8% since, to $391 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 296 payments — averaging $34.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$3K
- Novo Nordisk AS$1K
- Janssen Research & Development, LLC$1K
- Viiv Healthcare Company$855
- Gilead$642
- Johnson & Johnson$565
- plus $3K from 30 others
Across 3,444 payments — averaging $1247.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$1.9M
- Eli Lilly$1.1M
- Amgen$572K
- Janssen Research & Development, LLC$386K
- AbbVie$136K
- AstraZeneca$111K
- plus $94K from 4 others
What the payments were for
- Travel & lodging$3,58735%
- Food & beverage$6,34662%
- Education$3063%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 41 | $2,531 |
| Novo Nordisk AS | 4 | $1,231 |
| Janssen Research & Development, LLC | 9 | $1,162 |
| Viiv Healthcare Company | 32 | $855 |
| Gilead | 21 | $642 |
| Johnson & Johnson(2 entities) | 33 | $565 |
| Novo Nordisk | 21 | $450 |
| AstraZeneca | 23 | $398 |
| AbbVie(2 entities) | 20 | $379 |
| Merck | 10 | $226 |
| Novartis | 11 | $216 |
| Amgen | 9 | $205 |
| Lilly USA, LLC | 5 | $188 |
| Boehringer Ingelheim | 7 | $164 |
| EMD Serono, Inc. | 7 | $161 |
| GSK | 5 | $125 |
| Janssen Products, LP | 1 | $99 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $91 |
| Pfizer | 7 | $74 |
| Phathom Pharmaceuticals, Inc. | 3 | $64 |
| Theratechnologies Inc. | 2 | $56 |
| Lundbeck LLC | 2 | $42 |
| Bayer | 2 | $40 |
| Astellas Pharma US Inc | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Esperion Therapeutics, Inc. | 1 | $28 |
| Abbott | 1 | $26 |
| Dexcom, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Vyera Pharmaceuticals, LLC | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Antares Pharma, Inc. | 1 | $17 |
| United Therapeutics Corporation | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
| Napo Pharmaceuticals Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,239 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 252 | $1,257,879 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 123 | $556,116 |
| SerostimSomatropin | 25 | $514,468 |
| CabenuvaCabotegravir/Rilpivirine | 32 | $210,093 |
| OzempicSemaglutide | 165 | $194,966 |
| EliquisApixaban | 142 | $177,448 |
| JardianceEmpagliflozin | 116 | $150,643 |
| JulucaDolutegravir/Rilpivirine | 31 | $144,222 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 34 | $140,341 |
| MounjaroTirzepatide | 89 | $129,070 |
| DovatoDolutegravir Sodium/Lamivudine | 33 | $104,921 |
| DescovyEmtricitabine/Tenofov Alafenam | 27 | $104,908 |
| IsentressRaltegravir Potassium | 36 | $90,834 |
| TrulicityDulaglutide | 60 | $77,057 |
| FarxigaDapagliflozin Propanediol | 75 | $76,501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $642 | $1,503,128313 claims |
| Viiv Healthcare CompanyCabenuva, Juluca, Dovato, Triumeq, Tivicay | $855 | $572,912134 claims |
| EMD Serono, Inc.Serostim | $161 | $514,46825 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta, Spiriva Respimat | $164 | $224,741199 claims |
| Novo NordiskOzempic, Rybelsus | $450 | $220,902176 claims |
| Lilly USA, LLCMounjaro, Trulicity | $188 | $206,127149 claims |
| Johnson & JohnsonXarelto, Complera, Prezcobix | $565 | $186,765106 claims |
| PfizerEliquis | $74 | $177,448142 claims |
| MerckIsentress, Januvia | $226 | $109,86752 claims |
| AstraZenecaFarxiga | $398 | $76,50175 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $125 | $72,95199 claims |
| Janssen Products, LPSymtuza | $99 | $59,30111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Palm Springs
- Jorge RodriguezPalm Springs$246K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.